Both basic research and clinical studies have suggested that GLP-1 receptor agonists may have the potential to improve stroke recurrence and prognosis. LAMP was a multicenter, randomized controlled, prospective trial designed to evaluate the efficacy and safety of liraglutide (Victoza/Saxenda, Novo Nordisk) for the prevention of recurrent stroke after minor ischemic stroke or high-risk TIA in patients with diabetes
Filter-sterilize through a 0.22 m low-protein-binding membrane for sterile cell-culture workflows, and dilute into assay medium immediately before use to limit any extended bench-temperature exposure
There is no body composition analysis
Trial outcomes were measured in weeks and months , not days
This step helps determine whether Retatrutide is right for your needs and makes sure you receive the right guidance on dosing and how to use it properly
SDH-b knockout simulations also elucidated a shift towards a pseudohypoxic phenotype, characterised by increased lactate production and reduced pyruvate and glucose levels (Fig
